Evotec AG has appointed Cord Dohrmann as chief scientific officer and member of the management board, effective 1 September 2010. Dr Dohrmann is the chief executive of DeveloGen AG, a privately-owned German biotechnology company that is being acquired by Evotec. Dr Dohrmann has spent more than 20 years in biomedical research at leading academic institutions including the Max-Planck Institute, the Harvard Medical School and the Massachusetts General Hospital. He joined DeveloGen in 1999, eventually becoming the CEO.
Copyright 2010 Evernow Publishing Ltd